Analytical Questions on Enzymes

Definition, Classification of Enzyme, Coenzymes, Cofactors, Activators, and Proenzymes

Q1. Enzymes are biological catalysts. Discuss how their structure contributes to their specificity and catalytic efficiency.

Answer:

Enzymes have a unique three-dimensional structure that includes an active site — a specific region where the substrate binds. This structural complementarity between the enzyme and its substrate is described by:

• Lock and Key model – Enzyme and substrate fit precisely.

• Induced Fit model – Enzyme undergoes conformational change upon substrate binding, enhancing catalysis.

The specific amino acid residues in the active site participate in transient interactions, stabilizing the transition state, lowering activation energy, and increasing reaction rate.

Additionally, enzyme allosteric sites and cofactor binding sites further modulate activity and efficiency, allowing for regulation and specificity.

---

Q2. Classify enzymes and analyze how the classification correlates with the type of biochemical reactions in metabolism.

Answer:

Enzymes are classified into 6 major classes:

This classification mirrors the diversity of metabolic reactions, helping in systematic enzyme identification, understanding pathway mechanisms, and diagnosing enzyme defects in diseases.

---

Q3. Compare and contrast the roles of coenzymes, cofactors, and activators in enzyme function with suitable examples.

Answer:

Analysis:

• Coenzymes participate directly in chemical transformation (e.g., NAD⁺ accepts hydride ions).

• Cofactors (e.g., Mg²⁺ in kinases) stabilize enzyme or substrate.

• Activators alter enzyme conformation to an active state.

Their interplay ensures optimal enzyme function, and deficiency in any component can result in metabolic dysfunction.

---

Q4. A patient with vitamin B1 (thiamine) deficiency shows neurological symptoms. Analyze how this relates to enzyme activity involving coenzymes.

Answer:

Thiamine (Vitamin B1) is a precursor for Thiamine Pyrophosphate (TPP) — a coenzyme required by:

• Pyruvate dehydrogenase (links glycolysis and TCA cycle)

• α-ketoglutarate dehydrogenase (TCA cycle)

• Transketolase (HMP shunt)

Deficiency Impact:

• Impaired ATP production in neurons (high energy demand)

• Accumulation of lactate (due to pyruvate buildup)

• Leads to neurological symptoms (e.g., Wernicke’s encephalopathy, Beriberi)

Thus, vitamin deficiency affects coenzyme synthesis, reducing activity of key enzymes, especially in energy metabolism.

---

Q5. Proenzymes (zymogens) are synthesized in an inactive form. Critically analyze the physiological need for this mechanism with examples.

Answer:

Zymogens are inactive enzyme precursors that require proteolytic cleavage for activation.

Examples:

• Pepsinogen → Pepsin (by HCl in stomach)

• Trypsinogen → Trypsin (by enteropeptidase in duodenum)

Physiological Rationale:

• Prevents self-digestion of tissues (e.g., pancreas)

• Allows temporal and spatial control of enzyme activation

• Activation occurs only when and where needed

Failure in regulation (e.g., premature trypsin activation in pancreas) can cause acute pancreatitis. Thus, zymogens provide a safety mechanism in enzyme deployment.

---

Q6. Explain how metal ions as cofactors influence the catalytic activity of enzymes. Analyze with at least two examples.

Answer:

Metal ions can:

• Stabilize negative charges on substrates (e.g., Mg²⁺ with ATP)

• Participate in redox reactions (e.g., Fe²⁺, Cu²⁺)

• Help orient substrate or enzyme conformation

Examples:

1. Mg²⁺ in Hexokinase – Stabilizes ATP phosphate groups, facilitates phosphate transfer to glucose.

2. Zn²⁺ in Carbonic Anhydrase – Activates water molecule for nucleophilic attack on CO₂.

Conclusion:
Metal ions are essential cofactors that expand enzyme functionality and support structural and catalytic roles.

---

Q7. Differentiate between holoenzyme and apoenzyme. Predict what happens if a cofactor is deficient in the diet.

Answer:

Prediction:

• Cofactor deficiency → apoenzyme remains inactive → metabolic reactions slow or halt.

• Example: Fe²⁺ deficiency impairs cytochrome oxidase, affecting electron transport chain, leading to fatigue and muscle weakness.

Clinical Insight: Cofactor deficiencies often manifest as metabolic disorders or enzyme deficiencies, highlighting their essential roles.

Active Site, Enzyme Specificity, Enzyme-Substrate Complex Formation, Mechanism of Enzyme Action

Q1. Explain the different theories related to enzyme active site. How do these theories account for enzyme specificity?

Answer:

There are two major theories that explain how the active site of an enzyme interacts with its substrate:

1. Lock and Key Model (Emil Fischer, 1894):

• Enzyme active site has a specific shape complementary to the substrate — like a key fits into a lock.

• Explains high specificity.

• Limitation: Does not account for flexibility or conformational changes.

2. Induced Fit Model (Daniel Koshland, 1958):

• The enzyme’s active site is flexible.

• Substrate binding induces a conformational change in the enzyme to fit tightly.

• Better explains the dynamic nature of enzyme-substrate interaction and transition state stabilization.

Enzyme Specificity:

Both models explain specificity, but the induced fit model offers a more accurate view, especially for enzymes that undergo allosteric regulation or show broad substrate range.

---

Q2. Enzyme specificity is critical to metabolic control. Analyze the types of enzyme specificity with examples.

Answer:

Enzyme specificity refers to the ability of an enzyme to selectively bind and act on its specific substrate(s). Types include:

Analysis:

Specificity ensures efficiency and regulation of metabolic pathways and prevents wasteful or harmful side reactions.

---

Q3. Explain the formation of enzyme-substrate complex. Why is this step critical for catalysis?

Answer:

Enzyme-Substrate (ES) Complex Formation:

• The substrate binds to the enzyme’s active site forming an intermediate ES complex.

• This interaction involves hydrogen bonds, ionic interactions, hydrophobic interactions, and sometimes covalent bonds.

Importance:

1. Stabilizes the transition state, reducing activation energy.

2. Positions reactants optimally for bond breaking/forming.

3. Enables substrate orientation and microenvironment changes (e.g., pH).

4. Allows for regulation (via feedback or allosteric mechanisms).

Evidence:

• Michaelis-Menten kinetics supports ES complex formation.

• X-ray crystallography has shown ES complexes.

Thus, the ES complex is a central intermediate without which catalysis cannot proceed.

---

Q4. Describe the mechanism of enzyme action with special reference to lowering of activation energy.

Answer:

Mechanism of Enzyme Action:

1. Substrate binding to active site → ES complex.

2. Formation of transition state.

3. Conversion of substrate to product.

4. Product released, enzyme is regenerated.

How Enzymes Lower Activation Energy:

• Provide an alternate reaction pathway.

• Stabilize the transition state.

• Bring substrates in close proximity and correct orientation.

• Provide acid/base or covalent catalysis.

Energy Diagram Analysis:

• Activation energy (Ea) for uncatalyzed reaction is high.

• With enzyme, Ea is lowered, but ΔG (free energy change) remains the same.

Thus, enzymes accelerate reactions without altering thermodynamic feasibility.

---

Q5. A mutation alters the active site of an enzyme. Predict and analyze the effect on substrate binding and catalysis.

Answer:

Prediction:

• Mutation may change shape, charge, or hydrophobicity of the active site.

• This can affect:

  • Substrate binding (loss of complementarity)

  • Transition state stabilization

  • Catalytic residue function

Possible Effects:

1. Reduced or abolished activity (active site disrupted)

2. Altered specificity (enzyme may bind different substrates)

3. Gain of function (rare; new catalytic ability)

Example:

• Mutation in serine 195 of chymotrypsin leads to loss of protease activity.

• In sickle cell anemia, a mutation changes hemoglobin structure, showing how protein function is sensitive to structural changes.

Hence, enzyme structure-function relationship is critical, and even a single amino acid change can disrupt metabolism.

---

Q6. Compare the transition state and enzyme-substrate complex in terms of stability and function. Why do enzymes preferentially bind the transition state?

Answer:

Enzyme Preference:

• Enzymes bind transition states more tightly than substrates or products.

• This lowers activation energy by stabilizing the high-energy intermediate.

• Transition State Analogs are used as potent enzyme inhibitors (e.g., in drug design).

Factors Affecting Enzyme Activity

1. Question:

Why is there an optimal temperature for enzyme activity, and why does activity decrease beyond that point? Relate your answer to enzyme structure and function.

Answer:
Enzymes are protein catalysts, and their activity depends on maintaining a specific three-dimensional structure, especially the active site. As temperature increases:

• Molecular motion increases, leading to more frequent enzyme-substrate collisions, which increases reaction rate.

• This continues until the optimal temperature (typically around 37°C in humans), beyond which:

  • The weak non-covalent bonds (hydrogen bonds, ionic interactions) that stabilize the enzyme’s structure begin to break.

  • This causes denaturation, altering the active site conformation and reducing the enzyme’s ability to bind substrate.
    Thus, enzyme activity drops rapidly after surpassing the optimal temperature due to loss of functional structure, not just kinetic effects.

---

2. Question:

How does pH affect enzyme activity, and why does each enzyme have a specific pH optimum? Provide an example with physiological relevance.

Answer:
pH affects the ionization state of amino acid residues in the enzyme, especially those in the active site and substrate. This influences:

• Substrate binding

• Catalytic efficiency

• Protein stability

Each enzyme has a unique amino acid composition and thus a specific pH range where its structure is most stable and functional.

Example:

• Pepsin, a stomach enzyme, has an optimum pH of ~2, ideal for the acidic gastric environment.

• At neutral pH (e.g., pH 7), pepsin becomes inactive due to denaturation or improper ionization, impairing protein digestion.

Thus, deviation from optimal pH alters the enzyme’s charge distribution, leading to reduced activity or inactivation.

---

3. Question:

Enzyme activity increases with substrate concentration but plateaus at higher concentrations. Explain this behavior using the Michaelis-Menten equation.

Answer:
According to the Michaelis-Menten model:

v=Vmax⁡[S]Km+[S]v = \frac{{V_{\max}[S]}}{{K_m + [S]}}v=Km​+[S]Vmax​[S]​

• At low substrate concentrations ([S] ≪ Km), the reaction rate is directly proportional to [S].

• As [S] increases, more active sites become occupied.

• Eventually, all enzyme molecules are saturated with substrate, and the enzyme is working at Vmax.

• Beyond this point, increasing [S] further does not increase the rate, as no additional active sites are available.

This plateau demonstrates enzyme saturation, a core concept in enzyme kinetics, and emphasizes that enzymes are finite in number and capacity.

---

4. Question:

What is the difference between competitive and non-competitive inhibition? How do they affect Km and Vmax?

Answer:

• Competitive inhibitors mimic the substrate and bind to the active site, blocking substrate binding.

  • Increasing substrate outcompetes the inhibitor.

• Non-competitive inhibitors bind elsewhere, changing the enzyme’s conformation.

  • Substrate can still bind, but catalysis is less efficient or blocked.

Clinical Relevance:

• Methotrexate is a competitive inhibitor of dihydrofolate reductase, used in cancer therapy.

---

5. Question:

How would a deficiency in a coenzyme like NAD⁺ affect enzyme activity and cellular metabolism?

Answer:
Coenzymes like NAD⁺ are essential for redox reactions. They act as electron carriers, particularly in:

• Glycolysis

• TCA cycle

• Oxidative phosphorylation

If NAD⁺ is deficient:

• Enzymes like lactate dehydrogenase or pyruvate dehydrogenase cannot function efficiently.

• This impairs ATP production.

• Metabolic intermediates accumulate, and anaerobic glycolysis increases, leading to lactic acidosis.

Clinical Example:

• Niacin (Vitamin B3) deficiency leads to pellagra, characterized by dermatitis, diarrhea, dementia—due to impaired NAD⁺-dependent reactions.

---

6. Question:

Design an experiment to determine the effect of pH on an enzyme like amylase. What variables would you control, and what kind of graph would you expect?

Answer:
Experimental setup:

• Use buffer solutions at various pH values (e.g., pH 3–9).

• Keep enzyme and substrate concentrations, temperature, and incubation time constant.

• Measure product formation (e.g., maltose from starch) using a colorimetric assay (e.g., DNSA method).

Controls:

• Blank with no enzyme

• Blank with no substrate

• Inactivated enzyme sample

Expected result:

• A bell-shaped curve when plotting enzyme activity (y-axis) vs. pH (x-axis), with peak activity at optimal pH (e.g., ~7 for salivary amylase).

• Activity drops at extremes due to denaturation or improper ionization of active site residues.

---

7. Question:

How do enzymes maintain their activity in extreme environments, such as hot springs or acidic stomach conditions? What structural adaptations support this?

Answer:
Enzymes in extreme environments (e.g., thermophilic bacteria or acidophilic organisms) have structural adaptations that enhance stability:

• Increased number of ionic bonds and hydrogen bonds to resist denaturation.

• Hydrophobic core packing to stabilize tertiary structure.

• Altered amino acid sequences to prevent unfolding at high or low pH.

Example:

• Taq polymerase from Thermus aquaticus remains active at ~95°C due to high thermostability.

• Pepsin functions in the stomach at pH ~2 due to an amino acid composition that resists acid-induced unfolding.

These adaptations allow enzymes to retain structure and function in otherwise denaturing conditions.

---

8. Question:

How does enzyme concentration affect the rate of reaction if substrate concentration is not limiting? What happens when substrate becomes limiting?

Answer:

• When substrate is in excess, increasing enzyme concentration leads to a linear increase in reaction rate, as more active sites are available.

• When substrate is limiting, increasing enzyme concentration has no significant effect, because there isn’t enough substrate for all enzymes to act on.

This highlights the principle that enzyme activity is influenced by the availability of both enzyme and substrate, and for optimal activity, balanced concentrations are necessary.

Enzyme Inhibition and Its Clinical Significance

Section A: Conceptual & Mechanistic Questions

---

Q1. A patient overdosed on methanol. Explain the rationale for administering ethanol as an antidote.

Answer:
Methanol is metabolized by alcohol dehydrogenase to formaldehyde and formic acid, both of which are toxic. Ethanol acts as a competitive inhibitor of alcohol dehydrogenase, having a higher affinity than methanol. Administering ethanol saturates the enzyme, reducing methanol metabolism and allowing it to be excreted unchanged, thus preventing the formation of toxic metabolites.

---

Q2. Differentiate between competitive and non-competitive inhibition in terms of enzyme kinetics and reversibility. How does this apply in pharmacology?

Answer:

• Competitive inhibition: Inhibitor binds to the active site; Km increases, Vmax remains unchanged. Reversible by increasing substrate concentration.

• Non-competitive inhibition: Inhibitor binds to an allosteric site; Vmax decreases, Km remains unchanged. Not overcome by more substrate.

Pharmacological relevance:

• Statins are competitive inhibitors of HMG-CoA reductase (cholesterol synthesis).

• Allosteric inhibitors in cancer therapies (e.g., tyrosine kinase inhibitors) may exhibit non-competitive inhibition.

---

Q3. A new drug irreversibly inhibits cytochrome P450 enzymes. Predict and explain its effect on the metabolism of other co-administered drugs.

Answer:
Irreversible inhibition of cytochrome P450 enzymes decreases the metabolism of other drugs that are substrates of the same enzymes. This leads to drug accumulation, increasing the risk of toxicity. Clinically, this necessitates dose adjustments or avoidance of co-administration.

---

Q4. How does enzyme inhibition contribute to the therapeutic effect of ACE inhibitors in hypertension?

Answer:
ACE inhibitors block the angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced blood pressure, and decreased aldosterone secretion, making them effective antihypertensives.

---

Section B: Clinical Application Questions

---

Q5. A patient on warfarin develops unexpected bleeding after starting trimethoprim-sulfamethoxazole. Explain the interaction based on enzyme inhibition.

Answer:
Trimethoprim-sulfamethoxazole inhibits CYP2C9, the enzyme responsible for metabolizing warfarin. This inhibition reduces warfarin clearance, leading to elevated INR and increased bleeding risk. This is a clinically significant drug-drug interaction requiring warfarin dose adjustment or closer monitoring.

---

Q6. Why are monoamine oxidase inhibitors (MAOIs) contraindicated with certain foods and other drugs?

Answer:
MAOIs irreversibly inhibit monoamine oxidase, an enzyme that degrades tyramine (found in aged cheese, wine) and neurotransmitters. Tyramine accumulation can cause hypertensive crisis. Also, combining with SSRIs or TCAs can lead to serotonin syndrome due to excess serotonin levels.

---

Q7. In organophosphate poisoning, atropine and pralidoxime are administered. Explain their mechanism in relation to enzyme inhibition.

Answer:
Organophosphates irreversibly inhibit acetylcholinesterase, leading to acetylcholine accumulation and cholinergic crisis.

• Atropine blocks muscarinic receptors to reduce symptoms.

• Pralidoxime (2-PAM) reactivates the inhibited enzyme if given early, reversing the inhibition.

---

Q8. A patient with gout is prescribed allopurinol. How does enzyme inhibition contribute to its therapeutic effect?

Answer:
Allopurinol inhibits xanthine oxidase, the enzyme converting hypoxanthine and xanthine to uric acid. Inhibition reduces uric acid levels, preventing crystal formation and relieving symptoms of gout.

---

Section C: Interpretation and Data Analysis

---

Q9. You are given Lineweaver-Burk plots for an enzyme with and without an inhibitor. In the presence of the inhibitor, the x-intercept becomes less negative, but the y-intercept remains unchanged. Identify the type of inhibition and explain.

Answer:
The x-intercept becomes less negative (Km increases), but y-intercept (1/Vmax) remains constant → Competitive inhibition. This occurs because the inhibitor competes with the substrate for the active site, increasing the apparent Km, while Vmax remains the same.

---

Q10. A drug inhibits an enzyme by binding at a site distinct from the active site, and its effect is not reversed by increasing substrate concentration. What type of inhibition is this, and what is its likely effect on Vmax and Km?

Answer:
This describes non-competitive inhibition. The inhibitor binds allosterically, reducing the enzyme’s catalytic efficiency. Result: Vmax decreases, Km remains unchanged.

Regulation of Enzyme Activity

---

Section A: Conceptual Understanding

---

Q1. Why is regulation of enzyme activity more advantageous to the cell than regulation of enzyme synthesis?

Answer:
Regulating enzyme activity allows for rapid and reversible control of metabolic pathways in response to changing cellular conditions. It is more energy-efficient and faster than regulating enzyme synthesis, which involves transcription and translation (a slower and more resource-consuming process). This is critical in maintaining homeostasis.

---

Q2. Explain how feedback inhibition helps maintain metabolic balance in the cell using the example of the threonine to isoleucine pathway.

Answer:
In the threonine to isoleucine biosynthetic pathway, the first enzyme (threonine deaminase) is inhibited by the end-product isoleucine. When isoleucine levels rise, it binds allosterically to threonine deaminase, reducing its activity. This negative feedback loop prevents overproduction of isoleucine and conserves resources.

---

Q3. How does allosteric regulation differ from competitive inhibition? Give one example of a clinically important allosteric enzyme.

Answer:

• Allosteric regulation involves binding of regulatory molecules at sites other than the active site, causing conformational changes that affect enzyme activity (activation or inhibition).

• Competitive inhibition involves inhibitor binding at the active site, competing with the substrate.

Example: Phosphofructokinase-1 (PFK-1), a key regulatory enzyme in glycolysis, is allosterically inhibited by ATP and activated by AMP and fructose 2,6-bisphosphate.

---

Q4. Enzyme A is activated by phosphorylation, whereas enzyme B is inactivated by the same. Explain the significance of such differential regulation.

Answer:
Differential regulation via covalent modification (phosphorylation) allows coordinated control of opposing pathways. For example, in glycogen metabolism, glycogen phosphorylase (enzyme A) is activated by phosphorylation to promote glycogen breakdown, while glycogen synthase (enzyme B) is inactivated to prevent simultaneous synthesis. This ensures metabolic efficiency and prevents futile cycling.

---

Q5. Why do allosteric enzymes typically not follow Michaelis-Menten kinetics?

Answer:
Allosteric enzymes exhibit sigmoidal (S-shaped) kinetics instead of the hyperbolic curve seen in Michaelis-Menten kinetics because of cooperativity among subunits. Binding of substrate to one active site influences the affinity of other sites. This allows for more sensitive regulation around specific substrate concentrations, acting like a molecular switch.

---

Section B: Clinical Relevance

---

Q6. In a diabetic patient, how does regulation of PFK-1 contribute to hyperglycemia during fasting?

Answer:
During fasting, glucagon levels rise, leading to increased cAMP and activation of protein kinase A, which inhibits PFK-2 and lowers fructose 2,6-bisphosphate levels. This reduces PFK-1 activity, inhibiting glycolysis and promoting gluconeogenesis, contributing to elevated blood glucose in diabetes.

---

Q7. A patient is found to have a mutation in a regulatory site of an enzyme in the urea cycle. What might be the metabolic consequence?

Answer:
If the regulatory site is defective, the enzyme may not respond to activators (e.g., N-acetylglutamate activating carbamoyl phosphate synthetase I). This leads to reduced urea formation and accumulation of ammonia, resulting in hyperammonemia, which is toxic and can cause encephalopathy.

---

Q8. Explain how regulation of HMG-CoA reductase is targeted in the treatment of hypercholesterolemia.

Answer:
HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis and is regulated by feedback inhibition by cholesterol, phosphorylation, and gene expression. Statins inhibit this enzyme, mimicking feedback inhibition, reducing cholesterol synthesis. This also upregulates LDL receptors, lowering blood LDL levels.

---

Q9. A patient with Cushing’s syndrome shows excessive gluconeogenesis. Explain how enzyme regulation plays a role in this condition.

Answer:
In Cushing’s syndrome, high cortisol levels induce gene expression of gluconeogenic enzymes (e.g., PEP carboxykinase, glucose-6-phosphatase). This is a form of hormonal regulation via induction, leading to increased glucose production, contributing to hyperglycemia.

---

Section C: Applied/Case-Based Questions

---

Q10. A graph shows the activity of an enzyme before and after treatment with a regulatory molecule. The curve shifts from sigmoidal to hyperbolic. What type of regulation is indicated, and what might be the molecule involved?

Answer:
The shift from sigmoidal to hyperbolic indicates loss of cooperativity, suggesting that the regulatory molecule is an allosteric activator that stabilizes the R (relaxed) state of the enzyme. This makes substrate binding easier, resembling Michaelis-Menten kinetics. A possible example is AMP activating PFK-1.

Clinical Significance of Isoenzymes – CPK (CK), LDH, ALP

Section A: CPK (Creatine Phosphokinase / Creatine Kinase – CK) Isoenzymes

Q1. A 60-year-old man presents with chest pain. Serum CK-MB is elevated, but total CK is only mildly raised. What does this indicate, and why is CK-MB more useful than total CK in this case?

Answer:
CK-MB is more cardiac-specific than total CK. A disproportionate rise in CK-MB relative to total CK suggests myocardial injury, even when skeletal muscle CK-MM (which forms most of total CK) isn’t significantly elevated.

Clinical significance:

• Early detection of MI (CK-MB rises 4–6 hrs post-MI)

• Avoids false negatives in patients with low skeletal muscle mass

---

Q2. A patient with muscular dystrophy shows elevated total CK with a CK-MB fraction >10%. Does this always suggest myocardial infarction?

Answer:
No. In muscular dystrophy, CK-MM is elevated, and CK-MB may also rise due to muscle involvement, leading to a falsely high CK-MB percentage. However, troponin levels are typically normal, helping rule out MI.

Analytical point:

• Always interpret CK-MB with clinical context and other markers (e.g., troponin, ECG).

---

Q3. What is the significance of detecting CK-BB in serum, and in which clinical conditions might it be elevated?

Answer:
CK-BB is normally found in brain and smooth muscle, not in the serum.

Elevated CK-BB may indicate:

• CNS damage (e.g., stroke, trauma)

• Certain malignancies (e.g., prostate, colon cancer)

• Macro-CK (Type 2): CK-BB complexed with immunoglobulin

Clinical significance:

• May prompt neurological evaluation or cancer workup in unexplained cases

---

Section B: LDH (Lactate Dehydrogenase) Isoenzymes

Q4. A patient has elevated total LDH with LDH-1 > LDH-2 (“LDH flip”). What does this pattern suggest and how is it clinically useful?

Answer:
LDH flip (LDH-1 > LDH-2) is highly suggestive of acute myocardial infarction.

• Appears 12–24 hours after MI

• Persists for 5–10 days, useful when troponins normalize

LDH-1 predominates in:

• Heart

• RBCs

So it can also indicate hemolysis if other MI signs are absent.

---

Q5. How would you differentiate between liver disease and myocardial infarction based on LDH isoenzyme patterns?

Answer:

Thus, LDH-5 dominance supports hepatocellular damage, whereas LDH-1 dominance suggests cardiac or hemolytic origin.

---

Q6. A patient has macrocytic anemia with high LDH. LDH-1 and LDH-2 are elevated. What is the likely cause?

Answer:
The pattern of elevated LDH-1 and LDH-2 is characteristic of hemolytic anemia, particularly megaloblastic anemia (due to ineffective erythropoiesis).

Clinical reasoning:

• High LDH due to RBC lysis

• Correlate with low haptoglobin, high indirect bilirubin, reticulocytosis

---

Section C: ALP (Alkaline Phosphatase) Isoenzymes

Q7. A 45-year-old patient has elevated ALP. GGT is normal. What does this suggest about the source of ALP?

Answer:
Normal GGT with high ALP suggests a non-hepatic source, likely bone (e.g., Paget’s disease, osteomalacia, bone metastasis).

GGT (gamma-glutamyl transferase) is a hepatobiliary marker, so if it’s normal, ALP is unlikely from liver.

---

Q8. How does ALP isoenzyme analysis help differentiate between bone and liver pathology?

Answer:

Thus, isoenzyme analysis plus biochemical context helps identify the tissue source.

---

Q9. An elderly patient with prostate cancer has rising ALP levels. What is the likely cause and how can isoenzyme analysis help?

Answer:
Rising ALP in this context suggests bone metastasis, which increases bone ALP isoenzyme production.

Clinical use:

• Helps differentiate between liver metastasis vs bone metastasis

• Bone-specific ALP isoenzyme can be measured directly or via electrophoresis

---

Q10. In a child, high ALP is detected during routine screening. Should this always be investigated further?

Answer:
Not always. Physiological ALP elevation is common during growth spurts due to increased bone turnover.

Clues it’s benign:

• Child is otherwise asymptomatic

• Other liver markers normal

• ALP normalizes with age

Investigate further only if:

• Symptoms suggest liver or bone pathology

• GGT, calcium, phosphate are abnormal.

Clinical Significance of Enzymes: Diagnostic, Therapeutic & Analytical Uses

---

Section A: Diagnostic Use of Enzymes

---

Q1. A patient presents with chest pain. Troponin I is within normal range, but CK-MB is elevated. What does this indicate, and how do enzyme kinetics help in diagnosis?

Answer:
CK-MB rises within 4–6 hours after myocardial infarction, peaks at 24 hrs, and normalizes in 48–72 hrs.
Troponin I rises slightly later but stays elevated for 7–10 days.

In this case:

• CK-MB elevation + normal troponin suggests very early MI

• Repeat troponin testing after 3–6 hours can confirm

Clinical takeaway: Enzyme kinetics guide timing of sample collection and diagnostic accuracy.

---

Q2. Why are serum levels of amylase and lipase measured in suspected pancreatitis? Which is more specific and why?

Answer:

• Amylase and lipase are digestive enzymes released in pancreatic inflammation.

• Lipase is more specific because:

  • Remains elevated longer (up to 8–14 days)

  • Less influenced by salivary or renal disorders

Diagnostic role:

• Helps confirm acute pancreatitis

• Monitors treatment response

---

Q3. A patient with jaundice has elevated ALP and GGT, but normal AST and ALT. What type of liver pathology does this suggest, and why?

Answer:
This pattern suggests cholestatic liver disease (e.g., biliary obstruction), not hepatocellular damage.

• ALP and GGT are markers of bile duct injury

• AST/ALT are markers of hepatocyte injury

Thus, enzyme profile aids in localizing the site of liver damage.

---

Section B: Therapeutic Use of Enzymes

---

Q4. Explain the mechanism and clinical use of streptokinase in the management of myocardial infarction.

Answer:
Streptokinase activates plasminogen → plasmin, which dissolves fibrin clots.

Therapeutic use:

• Thrombolytic agent in acute MI, pulmonary embolism, and DVT

Clinical significance:

• Restores perfusion in occluded vessels

• Most effective when given within 6 hours of MI onset

---

Q5. Why is asparaginase used in the treatment of acute lymphoblastic leukemia (ALL)?

Answer:
ALL cells lack asparagine synthetase and rely on circulating asparagine.

Asparaginase:

• Depletes plasma asparagine

• Inhibits protein synthesis in leukemic cells → apoptosis

Therapeutic role:

• Selective toxicity against leukemic cells

• Part of chemotherapy protocols in pediatric ALL

---

Q6. A patient with exocrine pancreatic insufficiency is prescribed pancreatic enzyme replacement. What enzymes are included and what is their clinical benefit?

Answer:
Replacement therapy includes:

• Lipase

• Amylase

• Proteases (trypsin, chymotrypsin)

Clinical benefits:

• Improve digestion and absorption

• Reduce steatorrhea and malnutrition

Used in:

• Chronic pancreatitis

• Cystic fibrosis

• Post-pancreatectomy

---

Section C: Analytical Use of Enzymes (Lab/Diagnostic Tools)

---

Q7. Why are enzymes commonly used in clinical laboratory assays? Give an example.

Answer:
Enzymes are used because they:

• Provide specificity and sensitivity

• Enable quantitative analysis via colorimetric or kinetic methods

Example:

• Glucose oxidase in glucose meters:

  • Converts glucose → gluconic acid + H₂O₂

  • H₂O₂ reacts to form colored compound → measured spectrophotometrically

---

Q8. In a colorimetric assay for ALT, why is LDH added to the reaction mix?

Answer:
ALT reaction:
Alanine + α-KG → Pyruvate + Glutamate

To detect ALT activity, pyruvate is coupled with:
Pyruvate + NADH → Lactate + NAD⁺ (via LDH)

Role of LDH:

• Converts pyruvate to lactate

• NADH oxidation leads to decrease in absorbance at 340 nm

• The rate of NADH decrease = ALT activity

---

Q9. What is the role of horseradish peroxidase (HRP) in ELISA tests?

Answer:
HRP is an enzyme label used in enzyme-linked immunosorbent assay (ELISA).

Function:

• Catalyzes a reaction with chromogenic substrate (e.g., TMB)

• Produces a color change proportional to antigen/antibody concentration

Significance:

• Enables sensitive, specific detection of hormones, antibodies, antigens (e.g., HIV, HCG)

---

Section D: Integration & Interpretation

---

Q10. A patient with multiple bone fractures and poor wound healing has elevated ALP but normal calcium. What could be the underlying pathology, and which enzyme supports this diagnosis?

Answer:
Likely osteomalacia or vitamin D deficiency, where defective mineralization leads to bone turnover.

• ALP is elevated due to increased osteoblastic activity

• Normal calcium may occur due to compensation

Enzyme support:

• Elevated bone-specific ALP isoenzyme supports diagnosis

• Can be confirmed by low 25(OH) vitamin D